THE PRESENT INVENTION RELATES TO A PROCESS FOR THE SELECTION OF ANTI C-MET ANTIBODIES CAPABLE TO INHIBIT BOTH LIGAND-DEPENDANT AND LIGAND-INDEPENDENT ACTIVATION OF C-MET. MORE PARTICULARLY, SAID PROCESS IS BASED ON THE INHIBITION OF THE C-MET DIMERIZATION. IN ANOTHER ASPECT, THE PRESENT INVENTION CONCERNS SUCH ANTIBODIES AND COMPOSITIONS COMPRISING SUCH ANTIBODIES FOR THE PREPARATION OF A MEDICAMENT TO TREAT CANCER. DIAGNOSIS PROCESS AND KITS ARE ALSO PART OF THE INVENTION.